Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration

Klaffke, Stefanie; Kühn, Andrea A.; Plotkin, Michail; Amthauer, Holger; Harnack, Daniel; Félix, R.; Kupsch, Andreas

doi:10.1002/mds.21004

Cited by 83 publications

(53 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These observations should be taken into account in the diagnostic workup and/or when recruiting patients with suspected PD for treatment studies that intend to modify the disease progression. The fact that we did not observe postsynaptic D 2 receptor alterations in both patient groups is in line with previous studies that reported a slight degeneration of the caudate nucleus and the putamen across CBS and PD patients in the early disease course [7,12,17]. Therefore, IBZM-SPECT does not seem to be a sufficient diagnostic biomarker to assure a timely classification between these groups of patients.…”

Section: Discussionsupporting

confidence: 82%

“…However, the degree of atrophy in these regions and the involvement of other brain areas differ between clinical phenotypes [2,4]. In line with these findings, molecular imaging studies using positron emission tomography (PET) or single-photon emission computed tomography (SPECT) revealed functional brain alterations of different regions in CBS subtypes [5,6,7]. …”

Section: Introductionmentioning

confidence: 92%

See 1 more Smart Citation

FP-CIT- and IBZM-SPECT in Corticobasal Syndrome: Results from a Clinical Follow-Up Study

et al. 2016

View full text Add to dashboard Cite

Objective: To evaluate the striatal presynaptic dopamine transporter (FP-CIT-SPECT) and postsynaptic D₂ receptor (IBZM-SPECT) binding in patients with corticobasal syndrome (CBS). Background: FP-CIT and IBZM are commercially available and approved SPECT tracers for in vivo molecular imaging of pre- and postsynaptic nigrostriatal neuronal degeneration, but only few data for CBS are available. Methods: 23 patients meeting clinical criteria for early- to mid-stage CBS (disease duration ≤4 years) were examined with SPECT radiotracers FP-CIT and IBZM. All suspected CBS patients underwent a clinical follow-up examination and were re-evaluated after 19.7 ± 15.2 months (mean ± SD). Postmortem diagnosis was available for 2 patients. In patients who met research criteria for probable CBS at the final follow-up visit (n = 19; disease duration: 1.95 ± 0.91 years), SPECT binding values were compared to those of age- and gender-matched Parkinson's disease (PD) patients (n = 18, disease duration: 1.92 ± 0.91 years; clinical follow-up: 32 ± 29.6 months) and neurologically normal control subjects (n = 19). Results: In comparison to the healthy control subjects, both patient groups showed significant and asymmetric reduction of the striatal presynaptic dopamine transporter binding, but PD patients had significantly lower FP-CIT binding ratios than probable-CBS patients. FP-CIT binding values of probable-CBS patients and healthy controls demonstrated marked overlaps, and in 7 patients (39%) scans revealed no dopaminergic deficit. IBZM uptake did not show significant between-group differences. Conclusion: Our data indicate that in the early- to mid-stage CBS the degree of nigrostriatal impairment is only mild with a significant proportion of preserved dopamine transporter binding.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Introductionmentioning

confidence: 92%

FP-CIT- and IBZM-SPECT in Corticobasal Syndrome: Results from a Clinical Follow-Up Study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In contrast, [ 123 I]FP-CIT SPECT is effective in distinguishing DLB from AD, where ligand binding does not significantly differ from controls [142][143][144] . Frontotemporal dementia (FTD) may be associated with abnormal DAT scans [145,146] , while corticobasal degeneration (CBD) may occasionally present normal binding [147,148] . However, normally one would expect to be able to identify these disorders on clinical grounds.…”

Section: Atypical Parkinsonismmentioning

confidence: 99%

Single-Photon Emission Computed Tomography in Diagnosis and Differential Diagnosis of Parkinson’s Disease

Isaias

Antonini

2010

Neurodegener Dis

View full text Add to dashboard Cite

The diagnosis of Parkinson’s disease is clinical and relies on the presence of characteristic motor symptoms such as bradykinesia, rigidity and resting tremor with non-motor features increasingly recognized among the very early manifestations of the disorder. Functional imaging with tracers targeting specifically the dopamine system and regional brain function may show discrete abnormalities helping the clinician shorten considerably the diagnostic process. In this review, we will discuss the contribution of single-photon emission computed tomography imaging in supporting the clinical diagnosis (motor and pre-motor) of Parkinson’s disease and its differential diagnosis with essential tremor and other parkinsonian syndromes.

show abstract

“…Nuclear imaging methods for the dopaminergic system using SPECT or PET are reliable and objective diagnostic tools for Parkinson's syndromes. Among diverse radiopharmaceuticals for dopaminergic system, tropane derivatives, 123 I-FP-CIT or 123 I-beta-CIT, have been used to evaluate the dopamine transporters successfully [2][3][4]. Currently, 18 F-FP-CIT positron emission tomography (PET) is widely used in assessing the dopaminergic transporter [5,6], with a governmental drug approval in Korea.…”

Section: Introductionmentioning

confidence: 99%

Validation of Simple Quantification Methods for 18F-FP-CIT PET Using Automatic Delineation of Volumes of Interest Based on Statistical Probabilistic Anatomical Mapping and Isocontour Margin Setting

Kim

Paeng

et al. 2012

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose 18 F-FP-CIT positron emission tomography (PET) is an effective imaging for dopamine transporters. In usual clinical practice, 18 F-FP-CIT PET is analyzed visually or quantified using manual delineation of a volume of interest (VOI) for the striatum. In this study, we suggested and validated two simple quantitative methods based on automatic VOI delineation using statistical probabilistic anatomical mapping (SPAM) and isocontour margin setting. Methods Seventy-five 18 F-FP-CIT PET images acquired in routine clinical practice were used for this study. A studyspecific image template was made and the subject images were normalized to the template. Afterwards, uptakes in the striatal regions and cerebellum were quantified using probabilistic VOI based on SPAM. A quantitative parameter, Q SPAM , was calculated to simulate binding potential. Additionally, the functional volume of each striatal region and its uptake were measured in automatically delineated VOI using isocontour margin setting. Uptake-volume product (Q UVP ) was calculated for each striatal region. Q SPAM and Q UVP were compared with visual grading and the influence of cerebral atrophy on the measurements was tested. Results Image analyses were successful in all the cases. Both the Q SPAM and Q UVP were significantly different according to visual grading (P<0.001). The agreements of Q UVP or Q SPAM with visual grading were slight to fair for the caudate nucleus (κ00.421 and 0.291, respectively) and good to perfect to the putamen (κ00.663 and 0.607, respectively). Also, Q SPAM and Q UVP had a significant correlation with each other (P<0.001). Cerebral atrophy made a significant difference in Q SPAM and Q UVP of the caudate nuclei regions with decreased 18 F-FP-CIT uptake. Conclusion Simple quantitative measurements of Q SPAM and Q UVP showed acceptable agreement with visual grading. Although Q SPAM in some group may be influenced by cerebral atrophy, these simple methods are expected to be effective in the quantitative analysis of 18 F-FP-CIT PET in usual clinical practice.

show abstract

Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration

Cited by 83 publications

References 14 publications

FP-CIT- and IBZM-SPECT in Corticobasal Syndrome: Results from a Clinical Follow-Up Study

FP-CIT- and IBZM-SPECT in Corticobasal Syndrome: Results from a Clinical Follow-Up Study

Single-Photon Emission Computed Tomography in Diagnosis and Differential Diagnosis of Parkinson’s Disease

Validation of Simple Quantification Methods for 18F-FP-CIT PET Using Automatic Delineation of Volumes of Interest Based on Statistical Probabilistic Anatomical Mapping and Isocontour Margin Setting

Contact Info

Product

Resources

About